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Abstract – To maintain bone mass during bone remodelling, coupling is required between bone resorption
and bone formation. This coordination is achieved by a network of autocrine and paracrine signalling molecules
between cells of the osteoclast lineage and cells of the osteoblastic lineage. Mathematical modelling of signalling
between cells of both lineages can assist in the interpretation of experimental data, clarify signalling interactions
and help develop a deeper understanding of complex bone diseases. Several mathematical models of bone
cell interactions have been developed, some including RANK–RANKL–OPG signalling between cells and systemic
parathyroid hormone PTH. However, to our knowledge these models do not currently include key aspects of some
more recent biological evidence for anabolic responses. In this paper, we further develop a mathematical model
of bone cell interactions by Pivonka et al. (2008) [1] to include the proliferation of precursor osteoblasts into the
model. This inclusion is important to be able to account for Wnt signalling, believed to play an important role in
anabolic responses of bone. We show that an increased rate of differentiation to precursor cells or an increased
rate of proliferation of precursor osteoblasts themselves both result in increased bone mass. However, modelling
these different processes separately enables the new model to represent recent experimental discoveries such
as the role of Wnt signalling in bone biology and the recruitment of osteoblast progenitor cells by transforming
growth factor β. Finally, we illustrate the power of the new model’s capabilities by applying the model to prostate
cancer metastasis to bone. In the bone microenvironment, prostate cancer cells are believed to release some of
the same signalling molecules used to coordinate bone remodelling (i.e. Wnt and PTHrP), enabling the cancer
cells to disrupt normal signalling and coordination between bone cells. This disruption can lead to either bone
gain or bone loss. We demonstrate that the new computational model developed here is capable of capturing
some key observations made on the evolution of the bone mass due to metastasis of prostate cancer to the bone
microenvironment.
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1 Introduction
Bone is a dynamic living tissue which continuously un-
dergoes remodelling to ensure mineral homeostasis and to
repair micro damage [2, 3]. The two main bone cell types
executing bone remodelling are osteoclasts which resorb
the mineralised bone matrix and osteoblasts which deposit
osteoid (which subsequently becomes mineralised) [3].
The third cell type involved in bone remodelling are os-
teocytes (i.e., terminally differentiated cells derived from
mature osteoblasts that have been trapped in the miner-
alised bone matrix [4]). The entire ensemble of bone cells
contributing to bone remodelling is referred to as basic
multicellular unit (BMU) [5,6].
Within the BMU, pre-osteoblasts, which express RANKL
have been hypothesised to control the differentiation of
osteoclasts from hematopoietic progenitors [7–10]. The
bone resorption phase is subsequently followed by bone
formation, driven in part, by factors produced by the
osteoclast that stimulate osteoblastogenesis [9]. This cou-
pling between resorption and formation phase in BMUs is
required to maintain bone mass. Many bone pathologies,
such as osteoporosis, Paget’s disease and cancer metastasis
1Corresponding author. Email address:
pascal.buenzli@uwa.edu.au
to bone, are associated with the dysregulation of this cou-
pling process leading to abnormal bone loss or bone gain.
Mathematical modelling can be employed to interpret ex-
perimental data, clarify signalling interactions, investigate
therapeutic interventions, and to generally better under-
stand bone remodelling from a systems perspective [11].
Bone remodelling has been represented mathematically
in a variety of ways including bone cell population models
(ODEs) [1,12,13], continuum models (PDEs) [14–16] and
discrete cell models [17, 18]. The bone cell population
model by Lemaire et al. [13] proposes an interesting ap-
proach based on fundamental chemical reaction principles
such as material balance and mass action kinetics. This
model incorporates some of the most important bone bi-
ology known at that time. Extensions to include further
components of bone biology can be formulated using the
same framework. We have used this framework to include
new knowledge in bone biology in our bone cell population
model [1] (such as the expression of RANKL and OPG by
osteoblasts of various maturities) [1], and to introduce
a spatial variation in cells numbers to represent a single
basic multicellular unit [15]. We have also applied the
model by Pivonka et al. [1] to examine possible therapeutic
interventions to restore bone mass following dysregulation
of the RANK–RANKL–OPG signalling system [19], coupled
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this model to a pharmacokinetic model of denosumab to
explore the effect of different dosing regimes [20], and
studied osteolytic lesions in multiple myeloma [21].
However, while the model by Pivonka et al. [1] does
some things well, it does not capture the anabolic effects of
precursor osteoblast proliferation. Recent experimental ev-
idence suggests that Wnt signalling is a critically important
regulator of bone remodelling—Wnt signalling plays an im-
portant role in normal bone homeostasis under varying me-
chanical loading, and excessive Wnt signalling is responsible
for some osteopetrotic (excess) bone states [22,23]. In ad-
dition, recent clinical evidence demonstrates that adminis-
tration of intermittent PTH is an effective anabolic interven-
tion [23, 24]. The exact molecular mechanisms leading to
anabolic responses under intermittent PTH administration
are incompletely understood and probably multifactorial,
involving differential regulations of osteoblast differentia-
tion, proliferation and apoptosis [23]. While we do not
model intermittent PTH administration in this paper, it is
important to include these three cellular behaviours reg-
ulating the number of osteoblasts for future investigations.
In this paper, we thus further develop the model by Pivonka
et al [1] by introducing the proliferation of osteoblasts in a
way such that the new model is consistent with the original
model and can incorporate osteoblast proliferation through
Wnt signalling or via other signalling systems. We then
explore the effect of parameter changes in the new model
on net bone balance, and see that the new model is capable
of effectively representing osteopetrotic bone disease states
arising from disruption of normal osteoblastic proliferation.
Finally we illustrate the capabilities of the new model in
a complex bone disease that arises when prostate cancer
cells metastasise to the bone microenvironment. This
disease is characterised by a variable phenotype that often
involves net bone gain (coupled with focal bone loss) [25–
27], and finally net bone loss. We show that the new model
developed here can model bone gain and bone loss via
secretion of signalling molecules such as Wnt, PSA and PTHrP
by the prostate cancer cells.
2 Background
A recent review by Khosla et al. highlights the importance
of osteoblast development in the regulation of bone re-
modelling and the potential for therapeutic interventions
that target the osteoblastic lineage [28]. Osteoblasts are
mesenchymal cells derived from the mesoderm. Sequential
expression of several molecules (such as RUNX2 and OSX),
driven by signal transduction pathways, facilitates the dif-
ferentiation of the progenitor cell into a proliferating pre-
osteoblast, then into a bone matrix-producing osteoblast,
and eventually into a mechanosensory osteocyte or a bone-
lining cell (see Figure 1). As the cells of the osteoblastic
lineage differentiate, they produce molecules essential for
regulating BMU operation, including support of osteoclas-
togenesis and angiogenesis in a BMU. Active osteoblasts
secrete osteoid, which later mineralises to bone, while
osteocytes produce molecules that regulate BMU function.
The most extensively studied cell-kinetic model of os-
teoblast development is that of mechanically induced bone
formation in experimental orthodontics [29–31]. Based on
nuclear size, Roberts et al. [30] have characterised four
precursor cell types to the functional osteoblast. This dif-
ferentiation pathway has been confirmed (and refined) by
marker expression in vitro using functional assays [32,33].
Asymmetrically-dividing mesenchymal stem cells recruited
to the BMU give rise to a population of osteoblast progeni-
tors that are proliferating extensively (undergoing symmet-
ric division). These osteoblast progenitors differentiate into
pre-osteoblasts that undergo limited proliferation. Finally,
pre-osteoblasts differentiate in turn into non-proliferative
active osteoblasts [32].
Current bone biology literature identifies the central
role played by the Wnt signalling pathway in regulating
osteoblast development (Figure 1). Wnts are a family
of over 20 secreted glycoproteins crucial for the develop-
ment and homeostatic renewal of many tissues, including
bone [34]. Wnts stimulate canonical or non-canonical
signalling pathways by binding a receptor complex con-
sisting of LDL receptor-related protein 5 (LRP5) or LRP6
and one of ten Frizzled (Fz) molecules [35]. There are a
range of soluble ‘decoy molecules’ secreted that regulate
Wnt signalling including sclerostin, Dkk1,2,3 and SFRP1,2,3.
The canonical Wnt signalling pathway has been the most
extensively studied Wnt signalling pathway in osteoblasts.
Wnt activation involves the stabilization of β-catenin (via
inhibition of the GSK-3β, axin and APC complex), resulting
in the translocation of β-catenin TCF/LEF to the cell nucleus
and activation of various downstream transcription factors
critical for directing cell lineage and subsequent cell pro-
liferation [36]. Wnt signalling has three major functions
in osteoblastic lineage cells: (i) dictating osteoblast spec-
ification from osteo-/chondroprogenitors; (ii) stimulating
osteoblast proliferation; and (iii) enhancing osteoblast and
osteocyte survival (Figure 1).
This brief overview of osteoblast development and the
importance of Wnt signalling highlights the complexity of
potential bone cell interactions. A systems biology ap-
proach to bone remodelling can help understand these
interconnections and their importance for functional bone
remodelling [11]. It is only recently that a few mathemati-
cal models of interacting bone cells have been developed to
explore these fundamental aspects of the bone remodelling
sequence.
In Lemaire et al. [13], a bone cell population model for
bone remodelling is proposed and applied to the study of
bone diseases and therapeutic strategies. To restore bone
mass following catabolic pathologies (such as due to estro-
gen deficiency, vitamin D deficiency, and senescence), the
generation of pre-osteoblasts by differentiation is shown
by this model to be a powerful bone formative strategy.
This occurs despite coupling of formation to resorption
through cells of osteoblastic lineage expressing RANKL,
which binds to the RANK receptor of osteoclasts thereby
promoting osteoclast activation and bone resorption. The
computational model of bone remodelling of Lemaire et al.
has been refined by Pivonka et al. [1] who investigated the
effect of RANKL and OPG expression profiles on cells of the
osteoblastic lineage.
The aim of this paper is to investigate the effects of dif-
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Figure 1 – Osteoblast development and the Wnt signalling pathway. Canonical Wnt promotes the commitment of MSCs to the osteoblastic lineage,
stimulates osteoblast proliferation and enhances osteoblast and osteocyte survival [28].
ferent developmental stages of osteoblasts on bone remod-
elling. For this purpose, we include a transient-amplifying
(i.e. proliferating) stage in the osteoblastic lineage in the
bone cell population model of Pivonka et al. [1]. The
motivation for this inclusion is twofold:
1. It is known that the density of MSCs in bone marrow
is very low, and though MSCs are recruited to the BMU
site by TGFβ [37], it is likely the models of Refs [1,13]
rely on an unphysiological recruitment of a sufficient
number of pre-osteoblasts for the stimulation of a
sustained formative response. The fast increase in
osteoblast population required in a BMU remodelling
event is believed to involve proliferative cells (under-
going symmetric cell division), i.e., so-called transient-
amplifying osteoblast progenitors [38].
2. Hormones and cytokines regulate stages of osteoblast
development differently. The transient-amplifying
stage of osteoblasts is known to be strongly depen-
dent on various hormones, growth factors and other
molecules, such as Wnt, insulin-like growth factor
(IGF), prostaglandin E2 (PGE2) and estrogen [38–40].
The anabolic effect of intermittent PTH is believed to
operate through multifactorial regulation of osteoblast
generation at several developmental stages [23]. Also,
in some bone diseases, signalling by these hormones
and growth factors is disrupted, leading to an ab-
normal population of osteoblasts and a subsequent
imbalance of bone during remodelling. For these
reasons, a more accurate account of the transient-
amplifying stage of osteoblasts is essential for the
realistic modelling of such diseases.
However, we find that the inclusion of OBp proliferation
proposed in this paper has to be treated with some care
as it can lead both to an unstable dynamic system (not
converging to a steady state with finite cell densities) and to
potentially unphysiological system behaviour, for example
an anabolic response to continuous PTH administration,
which is experimentally known to be catabolic. These
issues are addressed in detail in this paper.
3 Description of the model
For simplicity, osteoblast progenitors and pre-osteoblasts
are pooled into a single proliferative cell type in our
model, which we call pre-osteoblast and denote by OBp.
Three stages of osteoblast development and two stages of
osteoclast development are included in the cell population
model.
Osteoclasts. Pre-osteoclasts (OCps) represent circulating
cells of hematopoietic origin. Pre-osteoclasts are assumed
to mature into active osteoclasts (OCas) upon activation of
their RANK receptor by the ligand RANKL. Active osteoclasts
are cells that resorb bone matrix at a rate kres assumed
constant (in volume per unit time). In the model, OCas are
assumed to undergo apoptosis at a rate enhanced by the
presence of TGFβ [1, 9, 15]. Thus, osteoclast development
can be summed up schematically as:
OCp
RANKL+−→ OCa TGFβ+−→ ;. (1)
Osteoblasts. Uncommitted osteoblast progenitors (OBus)
represent a pool of MSCs. These MSCs are assumed to com-
mit to the osteoblastic lineage by becoming pre-osteoblasts
(OBps) through activation of TGFβ signalling. In the model,
OBps represent transient-amplifying osteoblast progenitors
and they are therefore assumed to proliferate. Their
maturation into active osteoblasts (OBas) is assumed to be
downregulated by TGFβ. Active osteoblasts are cells that
form bone matrix at a rate kform assumed constant (in
volume per unit time). The fate of active osteoblasts is
either (i) to be buried in osteoid and become osteocytes;
(ii) to undergo apoptosis; or (iii) to become bone-lining
cells covering the surface of newly-formed bone. In our
model, the elimination of an OBa depletes the pool of
matrix-synthesising cells and thereby includes all three
possibilities. Thus, osteoblast development can be summed
up schematically as:
OBu
TGFβ+−→ OBp

TGFβ−−→ OBa −→ ... (2)
Regulatory factors. System-level coupling between the
osteoclasts and osteoblasts occurs because the concentra-
tions of the coupling signalling molecules TGFβ and of
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RANKL are themselves influenced by cellular actions. The
growth factor TGFβ is assumed to be stored in the bone
matrix and released into the microenvironment in active
form by the resorbing OCas [9,37,41]. The ligand RANKL is
assumed to be expressed on the surface of OBps. However
this expression can be blocked by binding to OPG, which
in turn is assumed to be produced in soluble form by
OBas [10, 42]. The generation of RANKL and of OPG by
osteoblasts is respectively upregulated and downregulated
by the systemic hormone PTH.
Governing equations. The osteoclast and osteoblast de-
velopment pathways (1)–(2) are transcribed mathemati-
cally as so-called ‘rate equations’ involving OCp, OCa, OBu,
OBp and OBa cell densities (number of cells per unit vol-
ume) [1,15]:
∂
∂ t
OCa = DOCp OCp −AOCa OCa, (3)
∂
∂ t
OBp = DOBu OBu −DOBp OBp +POBp OBp, (4)
∂
∂ t
OBa = DOBp OBp −AOBa OBa, (5)
where
DOCp(t) = DOCppiact
 
RANKL(t)/kRANKL
OCp

, (6)
AOCa(t) = AOCapiact
 
TGFβ(t)/kTGFβ
OCa

, (7)
DOBu(t) = DOBupiact
 
TGFβ(t)/kTGFβ
OBu

, (8)
DOBp(t) = DOBppirep
 
TGFβ(t)/kTGFβ
OBp

. (9)
In Eqs (3)–(5), source and sink terms are specified accord-
ing to transformation rates between cell types with first
order reaction rates to account for the effect of population
sizes. DOCp(t) is the differentiation rate of OCps into
OCas activated by RANKL, AOCa(t) is the apoptosis rate of
OCas activated by TGFβ, DOBu(t) is the differentiation rate
of OBus into OBas activated by TGFβ, and DOBp(t) is the
differentiation rate of OBps into OBas repressed by TGFβ.
The elimination rate of active osteoblasts,AOBa , is assumed
unregulated and constant: AOBa(t) ≡ AOBa . Activation and
repression of these rates by RANKL or TGFβ is expressed in
Eqs. (6)–(9) in terms of the dimensionless functions
piact(ξ) =
ξ
1+ ξ
, pirep(ξ) = 1−piact(ξ) = 1
1+ ξ
. (10)
These functional forms of piact and pirep are based on the
following assumptions. Ligands such as RANKL and TGFβ
modulate cell behaviours by binding to specific receptors on
the cells and triggering intracellular signalling pathways.
Following Refs [1, 13, 15], we assume that the signal
received by a cell corresponds to the fraction of occupied
receptors on the cell. This fraction is equal to piact(L/k),
where L is the extracellular ligand concentration and k
a binding parameter (dissociation binding constant) [43].
We do not model intracellular pathways explicitly but
relate a cell’s response to its input signal by assuming
a phenomenological relationship. Here, we assume that
a cell responds in proportion to receptor occupancy, i.e.
either in proportion to piact (for activation) or to pirep
(for repression).1 Note that since receptor occupancy is
a nonlinear function of the free ligand concentration, the
overall relationship between concentration of extracellular
ligand L and cell response in Eqs (6)–(9) is nonlinear.
The rate equations governing the concentrations of TGFβ,
RANK, RANKL, OPG and PTH are solved under the approxima-
tion that receptor–ligand binding reactions occur on a fast
timescale compared to cell responses. These equations are
presented in Appendix A.
The proliferation termPOBp OBp in Eq. (4) has been added
to the original system of equations of Ref. [1] to account
for the transient-amplifying stage of osteoblasts. This term
involves the proliferation rate POBp(t), which is related to
the average cell cycle period of pre-osteoblasts, τmitosis
OBp
, by
POBp(t) = ln(2)/τmitosisOBp (t). The proliferation rate POBp(t) is
controlled by a feedback mechanism and is therefore time
dependent (see Regulation of OBp proliferation below).
Finally, the matrix-resorptive activity of OCas and matrix-
synthesising activity of OBas influence the overall amount
of bone according to:
∂
∂ t
BV =−kresOCa + kformOBa, (11)
where BV stands for the volume fraction of bone matrix
in a representative volume element at the tissue scale.2
The quantity kresOCa represents the resorption rate (bone
volume fraction resorbed per unit time) and the quantity
kformOBa represents the formation rate (bone volume frac-
tion formed per unit time). All the parameter values of the
model are listed in Appendix B (Table 1).
The system of ODEs (3)–(5) together with Eqs. (27)–
(31) form a closed system that can be solved for the time
evolution of the three state variables OBp, OBa and OCa from
an initial condition. Eq. (11) can then be integrated to
provide the time evolution of the bone volume fraction.
Clearly, BV(t) is not a function of the current state only as
it depends on the integrated history of OCa(t) and OBa(t).
However, the bone volume fraction change rate ∂
∂ t
BV is a
function of the current state and will be a major model
output followed in this paper.
Regulation of OBp proliferation. In a single BMU, thou-
sands of active osteoblasts refill the cavity created by the
osteoclasts [3, 5]. Their continual recruitment from pre-
osteoblasts occurs at a rate that varies with the rate of
resorption. For a BMU that advances in bone at 40 µm/day,
an estimated rate of 120 active osteoblasts per day is
necessary to ensure that the whole perimeter of the BMU
cavity is covered by the bone refilling cells [3]. This
required recruitment rate of active osteoblasts is achieved
by a combination of differentiation from mesenchymal
stem cells near the tip of the blood vessel, and proliferation
of pre-osteoblasts between the blood vessel and cavity
walls [30, 32, 44]. Active osteoblasts in BMUs usually form
1Such a relationship has been shown to hold experimentally for
example in the context of human fibroblasts stimulated by epidermal
growth factor (EGF): the mitogenic response of these fibroblasts is linearly
dependent on the fraction of occupied EGF receptors [43, Fig. 6-7, p.249].
2The volume fraction of bone matrix is also equal to 1−Φ where Φ is
the ‘bone porosity’, i.e., the volume fraction of soft tissues (marrow, cells,
stroma) (compare with Ref. [3, Eq. (3.7)]).
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a single layer of cells [45], and so are limited in number
by the available bone surface area. It is likely that feedback
control mechanisms regulate pre-osteoblast proliferation to
limit the generation of active osteoblasts. We model this
control of cell population by limiting the proliferation rate
of pre-osteoblasts with the density of pre-osteoblasts, i.e.:
POBp(t) =
POBp(t)

1− OBp(t)
OBsatp

, if OBp(t)< OBsatp ,
0, if OBp(t)≥ OBsatp .
(12)
In Eq. (12), OBsatp is a critical density above which prolifera-
tion is entirely suppressed. The control of the proliferation
rate by the density of OBps may represent ‘contact inhibi-
tion’ or ‘pressure inhibition’ of proliferation and/or nutrient
or space restrictions in the BMU cavity. It may represent
a feedback control from newly-formed active osteoblasts
near the reversal zone. Indeed, pre-osteoblasts represent
the last stage of osteoblast development before maturation
into active osteoblasts. The density of pre-osteoblasts at a
given time used in Eq. (12) is thus approximately propor-
tional to the density of newly-formed active osteoblasts.
In Eq. (12), the remaining factor POBp(t) stands for
additional negative and/or positive regulations of the
proliferation of OBps as due to, e.g., Wnt signalling, PTH
administration, and other hormones and growth factors
that may play a role in mechanosensing [4, 46] or in the
development of osteoporosis, viz.
POBp(t)≡ POBp(Wnt(t), PTH(t), estrogen(t), IGF(t), TGFβ(t), ...).
(13)
Including all these regulations is beyond the scope of the
present work, but provides a clear direction for future
research. Here we will assume that in normal bone home-
ostasis, systemic levels of these signalling molecules lead
to a specific value of POBp and we will first investigate how
POBp as a parameter affects the remodelling behaviour of
the system. In Section 5, the model is applied to a complex
disease, and in this case, POBp is made dependent on Wnt
produced by metastatic prostate cancer cells.
We note that a time-dependent regulation of the pro-
liferation rate POBp(t) is essential to allow OBp cells to
(i) rapidly proliferate in early stages of osteoblastogene-
sis (when the density of pre-osteoblasts is low) and (ii)
reach a controlled steady state. Mathematically, a rapid,
exponential-like increase in the OBp population may occur
from Eq. (4) whenever POBp(t)−DOBp(t) is positive and
does not decrease too fast in time.3 On the other hand,
one sees from Eq. (4) that a necessary condition for the
OBp population to stay bounded and to converge to a
meaningful steady-state (with finite, positive cell densities)
is that
POBp(t)−DOBp(t)< 0, t →∞. (14)
The regulation of proliferation given in Eq. (12) enables us
to fulfill both requirements (i) and (ii).
3The density of OBps at time t has a contribution proportional to
exp
∫ t
0
dt ′ (POBp −DOBp )(t ′)
	
. This contribution increases faster than
any power law in time (exponential-like increase) provided that (POBp−DOBp )(t) is positive and does not decrease faster than or as fast as O(1/t).
Pre-osteoblasts generation: differentiation vs prolifera-
tion. Differentiation from MSCs and proliferation of pre-
osteoblasts are two different biological mechanisms that
enable the population of osteoblasts to reach the size
required in a BMU for functional remodelling. The relative
proportion of these two mechanisms in vivo has not been
quantified experimentally. Proliferation is a mechanism
that exponentially inflates any deviation in the original
population size. Proliferation thus provides a sensitive
control of the population and the potential for a quick
response. Of course if this is the dominant mechanism
for increasing the size of the OBp cell population, a small
change in proliferation rate may lead to a very large change
in the OBp cell population. We observe here that the
more proliferation becomes dominant, the more difficult it
becomes for the final cell population to be well-controlled,
as a small change in the rate of proliferation leads to a large
change in cell population. By contrast, differentiation of
MSCs is a mechanism that influences the initial population
of pre-osteoblasts. This provides a more stable mechanism
for controlling OBp cell population, but this has the poten-
tial disadvantage of requiring the recruitment and mainte-
nance of large numbers of MSCs. Clearly, if differentiation
is large, then proliferation needs to be limited to reach the
same population size.
For these reasons, it is helpful in the model to introduce
the relative proportion of OBu differentiation and OBp pro-
liferation as a parameter. We introduce the fraction ν such
that the generation of OBps in the steady state is achieved
with a fraction ν by OBp proliferation and with a fraction
1−ν by OBu differentiation. Denoting steady-state values
by an overline, the total generation rate of OBps in the
steady state is given by σOBp = DOBu OBu + P OBp OBp (see
Eq. (4)). The first term represents the contribution of OBu
differentiation and should thus account for a fraction 1−ν
of σOBp . The second term represents the contribution of OBp
proliferation and should thus account for a fraction ν of
σOBp . To determine the values of POBp and DOBu that satisfy
this, we impose
P OBp OBp = ν σOBp , DOBu OBu = (1−ν) σOBp , (15)
and use the fact that σOBp = DOBp OBp in the steady state.
With Eqs. (8),(9),(12), one then has from Eq. (15):
POBp(ν , OB
sat
p ) = ν DOBp pi
rep

TGFβ
kTGFβOBp

1− OBp
OBsatp
−1
, (16)
DOBu(ν , OB
sat
p ) = (1−ν) DOBp
pirep

TGFβ
kTGFβOBp

piact

TGFβ
kTGFβOBu
 OBp
OBu
. (17)
Therefore, provided that POBp = POBp(ν , OB
sat
p ) and DOBu =
DOBu(ν , OB
sat
p ) in Eqs. (12) and (8), the system reaches
for any value of ν a steady state characterised by the
same cell densities OBp, OBa and OCa and regulatory factor
concentrations TGFβ, RANKL, etc. as in Ref. [1] (despite the
additional proliferation term in Eq. (4)).4
The parameter ν enables us to investigate how the rela-
tive occurrence of OBp proliferation vs OBu differentiation in
4For ν = 0, the model of Ref. [1] is retrieved, except for a correction in
the production rate of RANKL, see Appendix A.
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osteoblastogenesis affects bone remodelling with a model
calibrated against the same healthy-state properties. To
understand how a dysregulation of OBp proliferation affects
bone remodelling in an anabolic disease, we will set in
Section 4
POBp = POBp(ν , OB
sat
p ) +∆POBp , (18)
DOBu = DOBu(ν , OB
sat
p ), (19)
and study the effects of ν , OBsatp and of the proliferation
rate ‘offset’ ∆POBp (which accounts for dysregulation) on
the steady state of the system.
4 Properties of the model
The steady-state cell densities represented by the model
correspond to physiological cell densities (averaged at the
tissue level) of a normal, healthy adult whose skeleton
undergoes remodelling. While a baseline of mesenchy-
mal stem cells and hematopoetic stem cells is implicitly
assumed, a bone remodelling event is not necessarily in-
duced. Indeed, the system of ODEs (3)–(5) governing
the evolution of OBp(t), OBa(t), and OCa(t) always admits
vanishing bone cell densities as a solution, whatever the
density of OBus and of OCps.
Specific signalling is required to commit these stem cells
to the osteoblastic and osteoclastic lineage. The induction
of a bone remodelling event appears to be a complicated
and poorly-understood process, that first requires bone lin-
ing cells retracting from the bone surface, and is followed
by the recruitment of osteoclasts on site. Our model is
not capable of modelling this induction process. However,
the specific signalling between osteoblasts and osteoclasts
mediated by RANKL and TGFβ forms a positive feedback loop
that leads any initial population of pre-osteoblasts or active
osteoclasts to a steady state characterised by positive cell
densitites OBp, OBa, OCa [1,15].
Anabolic potential of pre-osteoblast proliferation. Our
previous investigations of the bone remodelling model of
Ref. [1] have revealed that the RANK–RANKL–OPG pathway
is effective at inducing catabolic behaviour in response to
an increase in the RANKL/OPG ratio, but not effective at
inducing anabolic behaviour in response to a decrease in
the RANKL/OPG ratio [19]. By contrast, Figure 2 shows
that increasing POBp from a normal state with steady bone
volume is very effective at inducing an anabolic behaviour
of bone remodelling. But decreasing POBp from this state
is not effective at inducing a catabolic behaviour of bone
remodelling, even at high fractions ν .
The strong anabolic potential of pre-osteoblast prolifera-
tion occurs despite pre-osteoblasts expressing RANKL, which
by binding to the RANK receptor of osteoclasts promotes
osteoclast activation. This is similar to the bone formative
therapeutic strategy investigated by Lemaire et al. [13].
In fact, the dynamics shows that active osteoclasts are
only transiently increased by an increase in pre-osteoblast
density. The increase in OBps (which promotes osteoclasto-
genesis by increasing RANKL signalling to OCps) is followed
by a delayed increase in OBas. The latter cells produce
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Figure 2 – Steady-state value of bone volume change rate (in percent
volume fraction/day) plotted against POBp = POBp (ν , OB
sat
p ) + ∆POBp for
different fractions ν and a common value of OBsatp = 0.04 pM. Each curve’s
zero is marked by a dot and represent the value POBp (ν , OB
sat
p ) at which
bone volume is steady (see Eq. (18)). The vertical dashed line represents
the upper bound POBp (1, OB
sat
p ).
OPG, which binds competitively to RANKL. This reduces
the initial increase in RANKL signalling back to near-normal
levels. Another limiting factor for osteoclastogenesis by
RANKL signalling is the limited number of RANK receptors
on OCps. The generation rate of active osteoclasts saturates
when all RANK receptors on OCps are bound to RANKL.
It is noteworthy that the RANK–RANKL–OPG signalling
patway exhibits a pronounced ‘catabolic bias’ in the bone
remodelling models developed by Lemaire et al. [13] and
by Pivonka et al. [1, 19], while pre-osteoblast proliferation
exhibit a “complementary” ‘anabolic bias’ in the present
model. We emphasise that depending on the individual,
such biases may not be as pronounced in practice as the
models suggest. In the models, these biases can be partially
explained by the rapid saturation of the receptor–ligand
binding reaction rates (similarly to Michaelis–Menten en-
zyme kinetics) that limit the cells’ response to extracellular
ligands (via the ‘activator’ and ‘repressor’ functions piact and
pirep). As a consequence, cell behaviour is asymmetrical in
response to an increase or to a decrease of extracellular
ligands. The strength of this asymmetry depends on where
on the curves piact and pirep the normal state is assumed
to be. Normal ligand concentrations are likely to differ
across indivuals. In some individuals, this normal ligand
concentration may lie closer to the initial linear part, or
final saturated part of the functions piact, pirep than in other
individuals, and in this way, lead to a less pronounced
asymmetry of the cell’s response.
Response to ‘continuous’ PTH administration. The in-
clusion of OBp proliferation into the model introduces an
additional mechanism for osteoblastogenesis. The relative
importance of this additional mechanism is represented by
the parameter ν introduced in Section 3. High fractions ν
emphasise proliferation, which makes the model sensitive
to small variations in the initial populations. Depending on
the value of ν , different system behaviours may arise, as
illustrated in the following.
While an increase in pre-osteoblast proliferation is
observed to induce a strong anabolic response for a
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broad range of fractions ν (Figure 2), the magnitude of
the catabolic response to ‘continuous’ PTH administration
(which increases the RANKL/OPG ratio), is strongly depen-
dent on the choice of ν and OBsatp . Figure 3 shows the
steady-state resorption and formation rates reached by the
model for four combinations of (ν , OBsatp ) (Fig. 3(a)–(d))
under two externally-driven influences:
(i) An altered value of the OBp proliferation rate parame-
ter POBp (blue curve).
(ii) A continuous administration of PTH at rate Pext
PTH
(see
Eq. (31)) (red curves);
In Figure 3, the alteration of OBp proliferation may rep-
resents an alteration in the Wnt pathway. Continuous PTH
administration increases the concentration of PTH and thus
increases the RANKL/OPG ratio (see Eqs. (28), (30)), which
promotes osteoclastogenesis. It is well-known that con-
tinuous PTH administration leads to a catabolic response.
Strikingly, Figure 3(b) and (c) exhibit two examples of pairs
(ν , OBsatp ) that lead to an (as far as the authors are aware;
unphysiological) anabolic behaviour in response to an in-
crease in the RANKL/OPG ratio from the normal state. De-
creasing OBsatp and/or ν can restore the expected catabolic
behaviour. This is seen by comparing Figure 3(b)→(a)
(decrease in OBsatp ) and Figure 3(c)→(d) (decrease in ν).
The possibility for such unphysiological anabolic be-
haviour is new compared to the models by Lemaire et
al. [13] and Pivonka et al. [1]. However, this variability
may be advantageous, allowing the system to be adjusted
to specific patients or patient groups responding differently
to increased PTH. The anabolic or catabolic behaviour of
the model in response to increased RANKL/OPG ratio can
be measured in Figure 3 by the angle that the PTH curve
makes with the diagonal (corresponding to BV homeostasis)
at the point corresponding to the normal state. This angle
is shown in Figure 3(c) as ‘α’ and is plotted against ν
and OBsatp in Figure 4. Only the region corresponding to
negative angles (bottom-left region, in red, in Figure 4)
corresponds to a catabolic response to increased PTH. A
physiologic estimate of this angle constrains (ν , OBsatp ) to be
on the contour line corresponding to this angle in Figure 4,
leaving one degree of freedom. To retrieve the same
catabolic behaviour to continuous PTH administration near
the normal state for normal individuals as in Refs [1, 19],
we choose this angle to be ≈ −4.5◦. We note, however,
that the catabolic response to continuous PTH in the present
model is stronger at larger values of PTH administration
rates (not shown).
While continuous PTH administration (infusion) does not
induce an anabolic response, it is known that intermittent
PTH administration (daily injections) does lead to an an-
abolic response. This dual catabolic–anabolic mode of ac-
tion of PTH remains poorly understood [23]. It is instructive
to understand within our model how an anabolic response
to continuous PTH administration is obtained in Figure 3(b)
and (c). This anabolic response of the model occurs when
ν or OBsatp is large, i.e. when OBp proliferation is significant.
Increasing PTH increases RANKL/OPG and promotes osteo-
clastogenesis, which frees TGFβ in the microenvironment
and increases the OBp population. If OBp proliferation
is significant, this increase in OBp is amplified strongly
and eventually overcomes PTH-induced osteoclastogenesis,
which leads to an anabolic behaviour. As this behaviour
is not observed in vivo for continuous PTH administration,
it can be expected that the proliferative potential of pre-
osteoblasts is normally limited to the negative angle region
in Figure 4. We estimate that the balance between OBu dif-
ferentiation and OBp proliferation is probably somewhere
in the range 0.4 ® ν ® 0.6. This imposes a strong upper
limit to the parameter OBsatp (see Figure 4). For an angle≈−4.5◦, one has OBsatp ® 0.005 pM.
Finally, we note that intermittent PTH administration may
exert an action on a variety of regulatory pathways of bone
remodelling [23]. An overall anabolic response may be
obtained as a combined effects of anabolic and catabolic
disruptions of bone remodelling. This is the case for
example of point D in Figure 3(a), where the superposition
of an upregulation of pre-osteoblast proliferation and a
catabolic response to PTH administration still leads to an
overall anabolic response.
5 Application to prostate cancer
metastasis
Many bone pathologies are due to an altered bone balance
and an altered bone turnover rate during remodelling.
Bone imbalance is associated with under-refilling (bone
loss) or over-refilling (bone gain) in BMUs. Bone turnover
rate is associated with the number of active BMUs and
indicates how fast bone may be lost, gained, and/or turned
over. Our computational model represents bone remod-
elling at the tissue scale, where BMU quantities are spatially
averaged. At this scale, bone imbalance and abnormal
turnover rates are characterised by altered overall rates of
bone resorption kresOCa and bone formation kformOBa in the
representative volume element [6].
Prostate cancer develops metastases primarily to trabec-
ular bone of the pelvis, femur and vertebral bodies [47].
Several regulatory factors produced by the metastasising
prostate cancer cells (PCa) interfere with the normal regula-
tion of bone remodelling, leading to osteoblastic (anabolic)
lesions with underlying osteolytic (catabolic) areas [25,48,
49]. The molecules Wnt in particular, are believed to be
particularly important in establishing osteoblastogenesis in
these lesions [50]. Hall et al. [26] suggest that inhibition
of Wnt by Dkk1 at an early stage of PCa metastasis leads
to osteolytic lesions (due to expression of e.g. PTHrP or
RANKL by the PCa cells). These lesions help the PCa cells to
establish in the bone microenvironment. At a later stage,
PCa cells progressively increase the Wnt/Dkk1 ratio, resulting
in an increased osteoblastic response. Prostate cancer cells
also produce PSA, which cleaves PTHrP after amino acid
23 [48, 49, 51, 52]. The cleaved form PTHrP[1–23] fails to
activate the PTH receptor on osteoblasts, but is thought to
promote osteoblastogenesis [49].
The above time course of metastatic bone lesions can
be simulated in the model by prescribing an assumed
time course for the population of PCa cells and for their
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Figure 3 – Formation rate vs. resorption rate in the steady states obtained by varying OBp proliferation rates POBp (blue curve) and by varying RANKL/OPG
ratios (via continuous PTH administrations Pext
PTH
) (red curves). The various labelled points correspond to the following pairs (POBp , P
ext
PTH
): normal
≡  POBp (ν , OBsatp ), 0; A ≡ (0, 0); B ≡  2POBp (ν , OBsatp ), 0; C ≡  POBp (ν , OBsatp ), 400/day; and D ≡  2POBp (ν , OBsatp ), 200/day; Points E in (a), (b) and E’
in (b) correspond to states with no bone gain nor loss, but higher turnover rate.
expression of regulatory factors. To simplify, we assume
that a PCa tumour implants itself in trabecular bone and
locally grows over a characteristic time τPCa to a maximum
density PCamax:
PCa(t) = PCamax

1− exp(−t/τPCa). (20)
The PCa cells are assumed to produce PTHrP at a constant
rate βPTHrP, and PSA at a slowly increasing rate βPSA(t):
βPSA(t) = β
max
PSA

1− exp(−t/τPSA), (21)
The production rate of Wnt, βWnt(t), is assumed low initially
(or inhibited by Dkk1), but increases at later times:
βWnt(t) = β
max
Wnt
e(t−tWnt)/τWnt + βmin
Wnt /β
max
Wnt
e(t−tWnt)/τWnt + 1
. (22)
In Eq. (22), βmin
Wnt is the minimum production rate, β
max
Wnt is
the maximum production rate, tWnt is the time at which the
production rate increases and τWnt measures the duration
of that increase.
Both the catabolic influence of PTHrP and the anabolic
influence of Wnt produced by the PCa cells are taken into
account in the bone remodelling model. Cleavage of PTHrP
by PSA is taken into account, but not a potential anabolic
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Figure 4 – Angle between the continuous PTH administration response
curve and the diagonal at the point corresponding to the normal state in
Figure 3. Positive (negative) angles represent a response to increase in
PTH directed towards anabolic (catabolic) states. The four situations (a)–
(d) of Figures 3 are also represented. Only negative angles (red region)
represent the physiologically expected catabolic response to continuous
PTH administration. The grey region is not part of the allowable parameter
space as it corresponds to OBsatp < OBp.
influence of PTHrP[1–23]. Binding properties of PTHrP on
osteoblasts are assumed identical to those of wPTH, and
so the concentration of PTHrP is added to that of PTH in
Eqs. (28),(30). The Wnt produced by the PCa cells is
assumed to promote OBp proliferation according to:
POBp = POBp(ν , OB
sat
p )
h
1+αWnt
OBp
piact
 
Wnt(t)/kWnt
OBp
i
. (23)
As for the regulatory factors of bone remodelling, we
assume that the binding reactions involving PTHrP, PSA and
Wnt are fast. The concentration of these molecules quickly
reaches a quasi-steady state equal to the production rate
divided by the degradation rate [1, Eq. (25)]. We thus
have:
PTHrP(t) =
βPTHrP PCa(t)
DPTHrP + kPSAPTHrP PSA(t)
(24)
PSA(t) =
βPSA(t)PCa(t)
DPSA
(25)
Wnt(t) =
βWnt(t)PCa(t)
DWnt
, (26)
where DPTHrP, DPSA and DWnt are degradation rates. Table 2
in Appendix B lists the parameter values associated to
Eqs. (20)–(26).
The time course of the concentrations PTHrP(t) and
Wnt(t) in the bone microenvironment, and their effect on
the local bone volume fraction, are shown in Figure 5. It
has to be emphasised that BV(t) does not represent the time
course of the whole skeleton, but rather the evolution of a
small part of trabecular bone within a tissue sample. Other
regions of the bone might follow the same trend but have
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Figure 5 – Time courses of prostate-cancer-induced PTHrP(t), PSA(t) and
Wnt(t), and their effect on the local bone volume fraction. The assumed
evolution of the tumour and the rate of PSA and Wnt expression per PCa
cell is seen in the topmost plot. The metastatic lesions transition from
osteolytic to osteoblastic due to Wnt upregulating OBp proliferation.
a different time course. This hypothesis is supported by
histological evidence by Roudier et al. [27] in patients who
died with multiple bone metastases. This study shows that
both regions of osteolytic lesions and regions of osteoblastic
lesions are often found in the same individual.
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Figure 6 – Simulated resorption rate and formation rate due to prostate
cancer metastases to a tissue-scale portion of trabecular bone (blue line).
The dots on the line mark the elapsed weeks. The metastatic lesion
transitions from osteolytic to osteoblastic with increased turnover.
The joint evolution of the resorption rate and formation
rate of this simulated disease are displayed in Figure 6. One
sees that while the cancer develops osteoblastic lesions,
turnover rate is higher than normal, and so resorption rate
is also higher than normal. This is also consistent with the
description by Clarke and Fleisch [25] of prostate cancer
lesions to bone being often a combination of both an in-
crease in resorption and in formation at a same site. Here,
we have driven the transition between osteolytic lesions
and osteoblastic lesions by an increase in Wnt production
around tWnt. While several other factors are known to
influence the co-evolution of prostate cancer metastases
and bone lesions, this sequence of events may already
capture an aspect of metastatic lesions to bone, namely,
that the interference of cancer-cell-produced cytokines with
the normal biochemistry of bone remodelling can disrupt
normal remodelling signals and drive it to either catabolic
and anabolic imbalances.
6 Conclusions
Recent experimental evidence suggests that osteoblast pro-
liferation plays an important role in the regulation of
bone remodelling. In this paper, we have developed a
novel computational model of bone cell interactions that
includes osteoblast proliferation. This model takes into
account a catabolic regulatory mechanism of bone remod-
elling, mediated by the RANK–RANKL–OPG pathway, and a
new anabolic regulatory mechanism of bone remodelling,
driven by osteoblast proliferation. From our numerical
simulations the following observations have been made:
• Preosteoblast proliferation has the potential for a
strong anabolic bone response. Such a response could
be mediated by a variety of signalling molecules in-
cluding Wnt. The strong anabolic response of prolif-
eration complements the strong catabolic response of
RANKL observed in our model;
• To obtain physiologically meaningful results and a
manageable control of osteoblastogenesis, a balance
between osteoblast differentiation and proliferation is
essential, as well as a feedback regulation of prolifer-
ation. This feedback regulation probably originates in
the limited spatial and metabolic resources within the
confines of the BMU;
• Combining different strengths of pre-osteoblast prolif-
eration with continuous PTH administration broadens
the range of physiological bone responses that the
model can represent. This may enable a better repre-
sentation by the model of variability in the physiology
of individuals.
• The example of prostate cancer metastasis to bone
shows that the proposed catabolic and anabolic regu-
latory mechanisms of the model are able to simulate
the progression of a complex bone disease ranging
from catabolic to anabolic bone responses.
The numerical results indicate that the new model is
improved and able to capture essential features of bone
remodelling. Nevertheless, several aspects of the model
can be further improved. In particular the phenomeno-
logical description of Wnt regulation of osteoblast prolifer-
ation could include biochemical binding reactions between
different molecules regulating the binding properties of
Wnt to its receptor LRP5/6, such as sclerostin and Dkk1.
Most interestingly, the variability of the bone response
to a combination of continuous PTH administration and
perturbation of osteoblast proliferation suggests that future
developments of the model could shed light on the mech-
anisms underlying the difference between continuous PTH
administration and intermittent PTH administration.
Appendix A Rate equations of the
regulatory factors
The regulatory factor concentrations are governed by mass
kinetics rate equations. Ligand–receptor binding reactions
occur on a time scale much faster than the characteristic
times of cellular response (such as differentiation, apop-
tosis). The rate equations for the regulatory factors can
therefore be taken in their steady state (see Refs. [1, 15]
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for details). This gives:
TGFβ(t) =

Pext
TGFβ
(t) + nbone
TGFβ
kresOCa(t)

/DTGFβ (27)
RANKL(t) =
Pext
RANKL
(t) + β RANKL
OBp
OBp(t)
1+ kRANKL
RANK
RANK+ kRANKL
OPG
OPG(t)
×
¨
DRANKL +
β RANKL
OBp
OBp(t)
N RANKL
OBp
OBp(t)piact
 
PTH(t)/kPTH
OB,act
«−1
(28)
RANK = N RANK
OCp
OCp, (29)
OPG(t) =
Pext
OPG
(t) + βOPG
OBa
OBa(t)pirep
 
PTH(t)/kPTH
OB,rep

βOPG
OBa
OBa(t)pirep
 
PTH(t)/kPTH
OB,rep

/OPGsat + DOPG
(30)
PTH(t) =

Pext
PTH
(t) + βPTH

/DPTH (31)
In these equations, external production rates PextL (t) rep-
resent external sources (or sinks) of the protein L and are
assumed given. We provide in Table 1 the description and
values of the parameters of the model.
A slight change in the expression for RANKL in Eq. (28)
has been made compared to Ref. [1]. The production of
RANKL is now correctly proportional to the number of cells
that express RANKL. We have replaced βRANKL in Ref. [1, Eq.
(36)] by β RANKL
OBp
OBp(t).5 To ensure that the normal steady
state is unchanged by this correction, we take β RANKL
OBp
=
βRANKL/OBp. We note that the same inconsistency of having
a production rate of RANKL not scaled by the number of
osteoblasts is present in Ref. [13]. While many behaviours
of the model are marginally affected by this correction,
some inconsistent behaviours have been corrected. In
particular, increasing the number of pre-osteoblasts in our
model now increases the total number of RANKL (bound
and unbound) accordingly, and transiently increases the
number of active osteoclasts (until OPG, produced by OBas,
inhibits RANKL-activation of RANK). Previously, a decrease
in the number of active osteoclasts was observed in this
situation.
Appendix B Model parameters
The parameters of the bone remodelling model are listed
in Table 1. The additional parameters introduced for the
example of prostate cancer metastasis are listed in Table 2.
5We assume Model Structure 2 of Ref. [1], in which RANKL is only
expressed by OBps and OPG is only expressed by OBas.
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Table 1 – Model parameters
Symbol Value Description
OCp 1 · 10−3 pM pre-osteoclast density
OCa 1 · 10−4 pM steady-state density of active osteoclats
OBu 1 · 10−3 pM uncommitted osteoblast progenitors (MSC) density
OBp 1 · 10−3 pM steady-state density of pre-osteoblasts
OBa 5 · 10−4 pM steady-state density of active osteoblats
nbone
TGFβ
1 · 10−2 pM density of TGFβ stored in the bone matrix
kres 200 pM
−1day−1 daily volume of bone matrix resorbed per osteoclast
kform 40 pM
−1day−1 daily volume of bone matrix formed per osteoblast
DOCp 2.1/day OCp→ OCa differentiation rate parameter
AOCa 5.65/day OCa apoptosis rate parameter
DOBu 0.7/day OBu→ OBp differentiation rate parameter, value for ν = 0.5; Eq. (19)
DOBp 0.166/day OBp→ OBa differentiation rate parameter
POBp 0.054/day OBp proliferation rate parameter, value for ν = 0.5; Eq. (18)
AOBa 0.211/day OBa apoptosis rate
kRANKL
OCp
16.65 pM parameter for RANKL binding on OCp
kTGFβ
OCa
5.63 · 10−4 pM parameter for TGFβ binding on OCa
kTGFβ
OBu
5.63 · 10−4 pM parameter for TGFβ binding on OBu
kTGFβ
OBp
1.75 · 10−4 pM parameter for TGFβ binding on OBp
kPTH
OB,act 150 pM parameter for PTH binding on OB (for pi
act)
kPTH
OB,rep 0.222 pM parameter for PTH binding on OB (for pi
rep)
kRANKL
RANK
0.034/pM association binding constant for RANKL and RANK
kRANKL
OPG
0.001/pM association binding constant for RANKL and OPG
β RANKL
OBp
1.68 · 105/day production rate of RANKL per OBp
β OPG
OBa
1.63 · 108/day production rate of OPG per OBa
βPTH 250pM/day production rate of systemic PTH
N RANKL
OBp
2.7 · 106 maximum number of RANKL per OBp
N RANK
OCp
1 · 104 number of RANK receptors per OCp
OPGsat 2 · 108 pM OPG density at which endogeneous production stops
nbone
TGFβ
0.01pM density of TGFβ stored in the bone matrix
DTGFβ 2/day degradation rate of TGFβ
DRANKL 10/day degradation rate of RANKL
DOPG 0.35/day degradation rate of OPG
DPTH 86/day degradation rate of PTH
ν 0.5 fraction of OBp proliferation over OBu differentiation involved in the steady-state
density OBp
OBsatp 0.005 pM OBp density at which proliferation stops
Table 2 – PCa-specific parameters
Symbol Value Description
PCamax 5 · 10−3 pM maximum PCa density
τPCa 10 days duration of local PCa growth
τPSA 200 days duration of increase in PSA production
τWnt 50 days duration of increase in Wnt production
tWnt 200 days time of increase in Wnt production
βPTHrP 2 · 105/day production rate of PTHrP per PCa
βmax
PSA
1 · 104/day final production rate of PSA per PCa
βmin
Wnt
5 · 102/day minimum production rate of Wnt per PCa
βmax
Wnt
1 · 104/day maximum production rate of Wnt per PCa
DPTHrP 86/day degradation rate of PTHrP
DPSA 4/day degradation rate of PSA
DWnt 2/day degradation rate of Wnt
kPSA
PTHrP
60 pM−1day−1 parameter for PSA cleaving PTHrP
kWnt
OBp
2 pM parameter for Wnt binding on OBp
αWnt
OBp
2 amplification factor of PCa-induced OBp proliferation
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